Monoamine neurotransmitter functionalized poly(amidoamine) dendrimers for targeting of cabazitaxel to human prostate cancer cells
Source abstract
Abstract
Prostate cancer ranks as the second most prevalent solid malignancy in men. Androgen deprivation therapy is a common approach of treating metastatic prostate cancer. However, development of castrate resistance in patients over the course of treatment, non-specific drug distribution and low solubility of drugs are major challenges in the treatment of prostate cancer treatment. In this study, serotonin (ST), a monoamine neurotransmitter, was explored for the site-specific delivery of cabazitaxel (CBZ) to 5HT (5-hydroxytryptamine) receptors overexpressing prostate cancer cells. ST was conjugated to G4 PAMAM dendrimers (DEND) which have well defined, highly branched, nanoscale, multifunctional architecture to carry and enhance the solubility of hydrophobic drugs. This study demonstrates the successful synthesis, characterisation, and CBZ delivery using serotonin-polyethylene glycol-dendrimer complex (ST-PEG-DEND) to DU154 human prostate cancer cells. According to the findings, CBZ@PEG-DEND showed significantly higher time- and dose-dependent cytotoxicities and growth-inhibitory effects to DU145 cells in comparison to pure CBZ. Further, the cellular uptake studies revealed high cellular uptake of targeted and fluorescent conjugate (Rho@ST-PEG-DEND) in comparison to non-targeted fluorescent conjugate (Rho@PEG-DEND), highlighting the role of ST in improved delivery of CBZ to 5HT receptor overexpressed cancer cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · Cancer Research and Treatment · Prostate Cancer Treatment and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.10.3322/caac.21660 ↗
2. Albers Mohrman S, (Rami), Shani AB, McCracken A, Albers Mohrman S, Shani R AB, editors. Organizing for sustainable health care. Volume 2. Emerald Group Publishing Limited; 2012. pp. 1–39. https://doi.org/10.1108/S2045-0605(2012)0000002005.10.1108/S2045-0605(2012)0000002005 ↗
3. Cruz AKD, Vaish R. NewS & views screening — lessons to be learnt. Nat Rev Clin Oncol. 2021;0123456789:2–3.
4. Lim J, Onozawa M, Saad M, Ong TA, Malek R, Akaza H. Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: comparing between high- and middle-income Asian countries. Cancer Sci. 2021;112:2071–80. https://doi.org/10.1111/cas.14889.10.1111/cas.14889 ↗
5. Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18:663–72. https://doi.org/10.1038/s41571-021-00514-z.10.1038/s41571-021-00514-z ↗
6. Huggins C, Hodges CV. Studies on prostatic cancer i. the effect of castration, of Estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7. https://doi.org/10.3322/canjclin.22.4.232.10.3322/canjclin.22.4.232 ↗
7. Trojan L, Kiknavelidze K, Knoll T, Alken P, Michel MS. Prostate cancer therapy: standard management, new options and experimental approaches. Anticancer Res. 2005;25:551–61.
8. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for Low-Risk and Intermediate-Risk prostate cancer. JAMA Netw Open. 2019;2:1–13. https://doi.org/10.1001/jamanetworkopen.2018.8006.10.1001/jamanetworkopen.2018.8006 ↗
9. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45. https://doi.org/10.1038/35094009.10.1038/35094009 ↗
10. Dowling AJ, Tannock IF. Systemic treatment for prostate cancer. Cancer Treat Rev. 1998;24:283–301. https://doi.org/10.1016/S0305-7372(98)90062-7.10.1016/S0305-7372(98)90062-7 ↗
11. Cohen L, Assaraf YG, Livney YD. Novel selectively targeted multifunctional nanostructured lipid carriers for prostate cancer treatment. Pharmaceutics. 2022;14:1–21. https://doi.org/10.3390/pharmaceutics14010088.10.3390/pharmaceutics14010088 ↗
12. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al. MRI-Targeted or standard biopsy for Prostate-Cancer diagnosis. N Engl J Med 2018:1767–77. https://doi.org/10.1056/nejmoa180199310.1056/nejmoa1801993 ↗
13. Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34:1–8. https://doi.org/10.1515/dmpt-2018-0032.10.1515/dmpt-2018-0032 ↗
14. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389–96. https://doi.org/10.1038/nrc801.10.1038/nrc801 ↗
15. Tsai LC, Hsieh HY, Lu KY, Wang SY, Mi FL. EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. Nanomedicine. 2016;11:9–30. https://doi.org/10.2217/nnm.15.183.10.2217/nnm.15.183 ↗
16. Day KC, Hiles GL, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77:74–85. https://doi.org/10.1158/0008-5472.CAN-16-1656.10.1158/0008-5472.CAN-16-1656 ↗
17. Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC et al. ARTICLE R V β 3 Integrin-Targeted PLGA-PEG nanoparticles for enhanced Anti-tumor E Ffi Cacy of a Pt (IV). Prodrug 2012:4530–9.10.1021/nn301148e ↗
18. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, et al. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm. 2012;9:1705–16. https://doi.org/10.1021/mp3000309.10.1021/mp3000309 ↗
19. Rueda F, Eich C, Cordobilla B, Domingo P, Acosta G, Albericio F, et al. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology. 2017;222:989–97. https://doi.org/10.1016/j.imbio.2017.06.002.10.1016/j.imbio.2017.06.002 ↗
20. Fosbøl MØ, Kurbegovic S, Johannesen HH, Røder MA, Hansen AE, Mortensen J, et al. Urokinase-Type plasminogen activator receptor (uPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial. J Nucl Med. 2021;62:354–9. https://doi.org/10.2967/jnumed.120.248120.10.2967/jnumed.120.248120 ↗
21. Fatima S, Shi X, Lin Z, Chen G, qing, Pan X hua, Wu JCY et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol Oncol. 2016;10:195–212. https://doi.org/10.1016/j.molonc.2015.09.00810.1016/j.molonc.2015.09.008 ↗
22. Shajib S, Baranov A, Khan WI. Diverse effects of gut-derived serotonin in intestinal inflammation 2017. https://doi.org/10.1021/acschemneuro.6b0041410.1021/acschemneuro.6b00414 ↗
23. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs. 2003;12:805–23. https://doi.org/10.1517/13543784.12.5.805.10.1517/13543784.12.5.805 ↗
24. Banskota S, Ghia JE, Khan WI. Serotonin in the gut: blessing or a curse. Biochimie. 2019;161:56–64. https://doi.org/10.1016/j.biochi.2018.06.008.10.1016/j.biochi.2018.06.008 ↗
25. Seuwen K, Pouysségur J. Serotonin as a growth factor. Biochem Pharmacol. 1990;39:985–90. https://doi.org/10.1016/0006-2952(90)90276-Q.10.1016/0006-2952(90)90276-Q ↗
26. Buznikov GA, Lambert WH, Lauder JM. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Res. 2001;305:177–86. https://doi.org/10.1007/s004410100408.10.1007/s004410100408 ↗
27. Moiseiwitsch JRD, Raymond JR, Tamir H, Lauder JM. Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular explant cultures. Arch Oral Biol. 1998;43:789–800. https://doi.org/10.1016/S0003-9969(98)00067-3.10.1016/S0003-9969(98)00067-3 ↗
28. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate. 2004;59:328–36. https://doi.org/10.1002/pros.10374.10.1002/pros.10374 ↗
29. Paller CJ, Antonarakis ES. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;117–24. https://doi.org/10.2147/DDDT.S13029.10.2147/DDDT.S13029 ↗
30. Zhuang B, Du L, Xu H, Xu X, Wang C, Fan Y, et al. Self-assembled micelle loading Cabazitaxel for therapy of lung cancer. Int J Pharm. 2016;499:146–55. https://doi.org/10.1016/j.ijpharm.2015.12.073.10.1016/j.ijpharm.2015.12.073 ↗
31. Nishiyama N, Matsumura Y, Kataoka K. Development of polymeric micelles for targeting intractable cancers. Cancer Sci. 2016;107:867–74. https://doi.org/10.1111/cas.12960.10.1111/cas.12960 ↗
32. Jangid AK, Pooja D, Jain P, Rompicharla SVK, Ramesan S, Kulhari H. A nanoscale, biocompatible and amphiphilic prodrug of Cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells. Mater Adv. 2020;1:738–48. https://doi.org/10.1039/d0ma00189a.10.1039/d0ma00189a ↗
33. Hu J, Hu K, Cheng Y. Acta Biomaterialia Tailoring the dendrimer core for efficient gene delivery 2016.10.1016/j.actbio.2016.02.031 ↗
34. Mendes LP, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22:1–21. https://doi.org/10.3390/molecules22091401.10.3390/molecules22091401 ↗
35. Thakur S, Kesharwani P, Tekade RK, Jain NK. Impact of pegylation on biopharmaceutical properties of dendrimers. Polym (Guildf). 2015;59:67–92. https://doi.org/10.1016/j.polymer.2014.12.051.10.1016/j.polymer.2014.12.051 ↗
36. Ambekar RS, Choudhary M, Kandasubramanian B. Recent advances in dendrimer-based nanoplatform for cancer treatment: A review. Eur Polym J. 2020;126:109546. https://doi.org/10.1016/j.eurpolymj.2020.109546.10.1016/j.eurpolymj.2020.109546 ↗
37. Rai DB, Medicherla K, Pooja D, Kulhari H. Dendrimer-Mediated delivery of anticancer drugs for colon cancer treatment. Pharmaceutics 2023;15. https://doi.org/10.3390/pharmaceutics1503080110.3390/pharmaceutics15030801 ↗
38. Tunki L, Jangid AK, Pooja D, Bhargava SK, Sistla R, Kulhari H. Serotonin-Functionalized Vit-E nanomicelles for targeting of Irinotecan to prostate cancer cells. ACS Appl Bio Mater. 2020;3:5093–102. https://doi.org/10.1021/acsabm.0c00579.10.1021/acsabm.0c00579 ↗
39. Ezati N, Abdouss M, Rouhani M, Kerr PG, Kowsari E. Novel serotonin decorated molecularly imprinted polymer nanoparticles based on biodegradable materials; A potential self-targeted delivery system for Irinotecan. React Funct Polym. 2022;181:105437. https://doi.org/10.1016/j.reactfunctpolym.2022.105437.10.1016/j.reactfunctpolym.2022.105437 ↗
40. Pooja D, Kulhari H, Singh MK, Mukherjee S, Rachamalla SS, Sistla R. Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes. Colloids Surf B Biointerfaces. 2014;121:461–8. https://doi.org/10.1016/j.colsurfb.2014.06.059.10.1016/j.colsurfb.2014.06.059 ↗
41. Jain P, Bhagat S, Tunki L, Jangid AK, Singh S, Pooja D, et al. Serotonin-Stearic acid Bioconjugate-Coated completely biodegradable Mn3O4 nanocuboids for hepatocellular carcinoma targeting. ACS Appl Mater Interfaces. 2020;12:10170–82. https://doi.org/10.1021/acsami.0c00331.10.1021/acsami.0c00331 ↗
42. Fateminasab F, Bordbar AK, Shityakov S. Detailed chemical characterization and molecular modeling of serotonin inclusion complex with unmodified β-cyclodextrin. Heliyon 2019;5. https://doi.org/10.1016/j.heliyon.2019.e0140510.1016/j.heliyon.2019.e01405 ↗
43. Jangid AK, Patel K, Joshi U, Patel S, Singh A, Pooja D, et al. PEGylated G4 dendrimers as a promising nanocarrier for Piperlongumine delivery: Synthesis, characterization, and anticancer activity. Eur Polym J. 2022;179:111547. https://doi.org/10.1016/j.eurpolymj.2022.111547.10.1016/j.eurpolymj.2022.111547 ↗
44. Kumar PD, Kumar PV, Selvam TP, Rao KRSS. Prolonged drug delivery system of pegylated PAMAM dendrimers with a Anti-HIV drug. Res Pharm. 2013;3:8–17.
45. Zhang Y, Liu X, Li L, Guo Z, Xue Z, Lu X. An electrochemical Paracetamol sensor based on layer-by-layer covalent attachment of MWCNTs and a G4.0 PAMAM modified GCE. Anal Methods. 2016;8:2218–25. https://doi.org/10.1039/c5ay03241e.10.1039/c5ay03241e ↗
46. Luong D, Kesharwani P, Deshmukh R, Mohd Amin MCI, Gupta U, Greish K, et al. PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. 2016;43:14–29. https://doi.org/10.1016/j.actbio.2016.07.015.10.1016/j.actbio.2016.07.015 ↗
47. Song Y, Tian Q, Huang Z, Fan D, She Z, Liu X, et al. Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing Cabazitaxel as a drug delivery system. Int J Nanomed. 2014;9:2307–17. https://doi.org/10.2147/IJN.S61220.10.2147/IJN.S61220 ↗
48. Madhuri G, Nagaraju R, Killari KN. Enhancement of the physicochemical properties of poorly soluble Lovastatin by co-crystallization techniques - In vivo studies. Indian J Pharm Sci. 2020;82:249–59. https://doi.org/10.36468/pharmaceutical-sciences.645.10.36468/pharmaceutical-sciences.645 ↗
49. Sun B, Paraskevopoulos G, Min J, Rossdeutcher R, Ghosh S, Quinn B, et al. Topical drug delivery of concentrated Cabazitaxel in an α-Tocopherol and DMSO solution. Adv Sci. 2023;10. https://doi.org/10.1002/advs.202302658.10.1002/advs.202302658 ↗